BARDA continues support of pre- and post-exposure Anthrax vax

Intramuscular injection of an anthrax prophylactic has sustained the attention of the U.S. Biomedical Advanced Research & Development Authority (BARDA) to the tune of $68 million. New Jersey-based Elusys announced winning the award to develop the humanized and de-immunized monoclonal antibody, Anthim.

The company says Anthim is a preventive both before and after anthrax exposure. In the post-exposure case, treatment must be administered before symptoms show.

The intramuscular injection is another selling feature, since it allows for rapid administration to large numbers of people outside of a medical setting. It's intended to require no trained medical personnel, intravenous bags, sterile mixing or other IV prep, according to a statement.

The new funding supplements a previous contract, totaling up to $143 million over 5 years, for the drug's development for symptomatic patients. Elusys VP Leslie Casey said that one intramuscular dose provided a 92% survival rate during animal testing when the drug was administered 18 hours after exposure to anthrax. "Surviving animals tested negative for anthrax bacteria by study day 14."

- see the Elusys statement

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.